Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Lipopeptide Hydrogel Possesses Adjuvant-Like Properties for the Delivery of the GPC-3 Peptide-derived Antigen
Date
2025-01-01
Author
Mathes, Tess G.
Kim, Uijin
Jeon, Keuna
Estevez, Paulina Juarez
Terasaki, Miya
Ermiş Şen, Menekşe
O'Raw, Aliesha
Jucaud, Vadim
Khademhosseini, Ali
Falcone, Natashya
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
26
views
0
downloads
Cite This
Peptide-based cancer vaccines are attractive as they can elicit antigen-specific cytotoxic T lymphocytes (CTLs) with minimal side effects. However, low immunogenic responses have delayed their translation to the clinic. Adjuvants, which are required in vaccines to boost immunogenicity, currently lack the ability to simultaneously induce specific cell-mediated effects and act as a delivery system. These concerns are addressed by engineering a novel class of adjuvants; lipopeptide hydrogels (LPHs). Myristic acid conjugated to diphenylalanine (Myr-FF), myristic acid diphenylalanine-tyrosine (Myr-FFY), and combination gel (Cogel) are synthesized and tested for immune modulation. They are loaded with a glypican-3 (GPC-3)-derived peptide designed for targeting hepatocellular carcinoma (HCC). The LPHs enable the sustained release of the GPC-3 peptide over two weeks, followed by antigen uptake by antigen-presenting cells (APCs). These LPHs are shown to act as a toll-like receptor (TLR)-2 agonist, cause an upregulation of costimulatory molecules (CD80, CD83, CD86), and the secretion of cytokines (IL-6, TNF-α, etc). In vivo studies showed that LPHs cause an increase in leukocyte infiltration within LNs with no visible toxicity. These LPHs exhibit adjuvant-like characteristics, thus providing a promising platform for future investigation in enhancing peptide-based vaccine efficacy.
Subject Keywords
adjuvants
,
biomaterials
,
cancer immunotherapy
,
immunomaterials
,
peptide hydrogels
,
supramolecular assembly
,
vaccine
URI
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85215688156&origin=inward
https://hdl.handle.net/11511/113713
Journal
Advanced Functional Materials
DOI
https://doi.org/10.1002/adfm.202413870
Collections
Biomaterials and Tissue Engineering Application and Research Center (BİOMATEN), Article
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
T. G. Mathes et al., “Lipopeptide Hydrogel Possesses Adjuvant-Like Properties for the Delivery of the GPC-3 Peptide-derived Antigen,”
Advanced Functional Materials
, pp. 0–0, 2025, Accessed: 00, 2025. [Online]. Available: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85215688156&origin=inward.